Photodynamic therapy (PDT) based on the photosensitizer hematoporphyrin derivative (HPD) for treatment of human cancer tumors rests on the development of practical laser sources operating in the required spectral band (630 plus or minus 5 nm) with high average power ( greater than 1 W). Approaches to the development of lasers for HPD phototherapy based on the copper vapor laser and utilizing new dye laser techniques are reported. Initial experiments concentrated on studies of copper-laser-pumped dye amplifier systems locked to the lambda 627. 8-nm wavelength of the gold laser. Amplifier efficiencies and gain were measured as a function of injection power pump power, dye concentration, dye mixture, and solvent. Maximum conversion efficiencies of 30% and single-pass gains of 15-20 have been obtained.
|Title of host publication||Conference on lasers and electro-optics: 26 April-1 May 1987, OSA/IEE, Baltimore, Maryland|
|Place of Publication||Washington, DC|
|Publisher||Optical Society of America (OSA)|
|Number of pages||1|
|Publication status||Published - 1987|